Akèy › Leksemi mieloïd egi › Florid › Tampa
Etid klinik pou Leksemi mieloïd egi nan Tampa, FL
29 etid pou Leksemi mieloïd egi ap chèche patisipan nan sit nan ak bò kote Tampa (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 2/3
- Moffitt Cancer Center /ID# 279192, Tampa
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Moffit Cancer center, Tampa
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Ap rekriteFaz 3
- Tampa General Hospital, Tampa
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
A Study of BGB-11417 in Participants With Myeloid Malignancies
Ap rekriteFaz 1/2
- Tampa General Hospital, Tampa
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Ap rekriteFaz 1/2
- Moffitt Cancer Center and Research Institute Hospital, Tampa
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Ap rekriteFaz 1/2
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Ap rekriteFaz 3
- Saint Joseph's Hospital - Tampa, Tampa
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- Moffitt Cancer Center & Research Institute, Tampa
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Ap rekriteFaz 1
- H Lee Moffitt Cancer Center & Research Institute, Tampa
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Ap rekriteFaz 3
- Moffitt Cancer Center, Tampa
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
Ap rekriteFaz 1
- Moffitt, Tampa
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Ap rekriteVolontè an sante akeyi
- Moffitt Cancer Center, Tampa
Study of REM-422 in Patients With AML or Higher Risk MDS
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Etid Leksemi mieloïd egi nan lòt vil
- Houston, TX85 etid
- New York City, NY51 etid
- Boston, MA44 etid
- Seattle, WA41 etid
- Baldwin Park, CA40 etid
- Columbus, OH35 etid
- Philadelphia, PA34 etid
- Durham, NC33 etid
- Atlanta, GA31 etid
- Chicago, IL26 etid
- Portland, OR25 etid
- Washington, DC24 etid
Lòt etid nan Tampa
- Kansè Poumon ki pa ti selil51 etid
- Kansè nan tete43 etid
- Kansè (tout kalite)39 etid
- Kansè kolorektal34 etid
- Kansè Metastatik29 etid
- Kansè poumon29 etid
- Kansè pankreyas26 etid
- Kansè ovè21 etid
- Melanom19 etid
- Sendwòm myelodisplastik19 etid
- Kansè pwostat18 etid
- Ensifizyans kadyak18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.